Korean J Urol.  1992 Aug;33(4):611-617.

Effect of combination therapy with vinblastine, adriamycin and interferon-alpha, gamma on human renal cell carcinoma cell lines

• Lee ES
• Kim HH
• Ahn HJ
• Min KJ
• Lee C

Abstract

In vitro study was performed to evaluate the effect of combination therapy with vinblastine. adriamycin and interferon-alpha, gamma on human renal cell carcinoma cell lines. Three renal cell carcinoma cell lines. Caki-1, Caki-2, A498, were used. The cytotoxicity was measured by MTT assay. The concentrations of vinblastine and adriamycin was fixed to IC50 after cytotoxicity assessment and 10, 100, 1.000, 10.000 IU/ml of interferon alpha, gamma were combined. The cytotoxicity by interferon alpha or gamma alone increased according b the concentration and 10 to 30% cytotoxicity were showed in all three renal cell carcinoma cell lines. The synergistic effect was found in interferon alpha plus adriamycin and interferon gamma plus Vinblastine in Caki-2. The additive effects was found in interferon alpha plus vinblastine in Caki-2. interferon gamma plus vinblastine and interferon alpha plus adriamycin in Cancer cell line. Interferon gamma showed more tan additive effect in all three cell lines combined with adriamycin. These findings suggest that interferon alpha or gamma could be used in combination with adriamycin. Further studies including in vivo studies are mandatory before human application.

Keyword

renal cell carcinoma; interferon alpha

MeSH Terms

Carcinoma, Renal Cell*
Cell Line*
Doxorubicin*
Humans*
Inhibitory Concentration 50
Interferon-alpha*
Interferons
Triacetoneamine-N-Oxyl
Vinblastine*
Doxorubicin
Interferon-alpha
Interferons
Triacetoneamine-N-Oxyl
Vinblastine